Do general and multiple sclerosis specific quality of life instruments differ?

被引:21
作者
Moore, F
Wolfson, C
Alexandrov, L
Lapierre, Y
机构
[1] McGill Univ, Dept Neurol, Ctr Clin Epidemiol & Community Studies, Montreal, PQ H3A 2T5, Canada
[2] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 2T5, Canada
[3] Montreal Neurol Hosp, McGill Multiple Sclerosis Clin, Montreal, PQ, Canada
关键词
D O I
10.1017/S0317167100002857
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Quality of life instruments provide information that traditional outcome measures used in studies of multiple sclerosis do not. It is unclear if longer, disease-specific instruments provide more useful information than shorter, more general instruments, or whether patients prefer one type to another. Methods: We conducted a cross-sectional study of quality of life in a multiple sclerosis clinic population using a mailed questionnaire that combined three different quality of life instruments; the SF-36, the Multiple Sclerosis Quality of Life Instrument-54, and the EuroQol EQ-5D. We assessed the feasability of using each instrument and patient preference for each, calculated correlation coefficients for the summary scores of each instrument and other measures of disease severity, and calculated odds ratios from proportional odds models comparing each instrument with the Expanded Disability Status Scale. Results: We did not find substantial differences between the three instruments. All were well-received by patients, and over 75% felt that the combination of the three instruments best assessed their quality of life. For each instrument there was substantial variability between patients with similar quality of life scores in terms of their disability (as assessed by the Expanded Disability Status Scale and their own perception of their disease severity and quality of life (on simple 1-10 scales). Conclusions: Quality of life instruments are easy to use and well-received by patients, regardless of their length. There do not appear to be clinically important differences between general and disease-specific instruments. Each instrument appears to measure something other than a patient's disability or perception of their own disease severity or quality of life.
引用
收藏
页码:64 / 71
页数:8
相关论文
共 47 条
[11]   Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504
[12]  
Ebers GC, 1999, LANCET, V353, P678
[13]   An empirical comparison of four generic health status measures - The Nottingham Health Profile, the Medical Outcomes Study 36-item Short-Form Health Survey, the COOP/WONCA charts, and the EuroQol instrument [J].
EssinkBot, ML ;
Krabbe, PFM ;
Bonsel, GJ ;
Aaronson, NK .
MEDICAL CARE, 1997, 35 (05) :522-537
[14]  
FABIO RP, 1997, PHYS THER, V77, P1704
[15]   Recent developments in the assessment of quality of life in Multiple Sclerosis (MS) [J].
Fischer, JS ;
LaRocca, NG ;
Miller, DM ;
Ritvo, PG ;
Andrews, H ;
Paty, D .
MULTIPLE SCLEROSIS JOURNAL, 1999, 5 (04) :251-259
[16]  
FLETCHER A, 1992, BMJ-BRIT MED J, V305, P1146
[17]   Does adding MS-specific items to a generic measure (the SF-36) improve measurement? [J].
Freeman, JA ;
Hobart, JC ;
Thompson, AJ .
NEUROLOGY, 2001, 57 (01) :68-74
[18]  
GULICK EE, 1993, ACTA NEUROL SCAND, V88, P87
[19]  
Jacobs LD, 1996, ANN NEUROL, V40, P480
[20]   COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
JOHNSON, KP ;
BROOKS, BR ;
COHEN, JA ;
FORD, CC ;
GOLDSTEIN, J ;
LISAK, RP ;
MYERS, LW ;
PANITCH, HS ;
ROSE, JW ;
SCHIFFER, RB ;
VOLLMER, T ;
WEINER, LP ;
WOLINSKY, JS ;
BIRD, SJ ;
CONSTANTINESCU, C ;
KOLSON, DL ;
GONZALEZSCARANO, F ;
BRENNAN, D ;
PFOHL, D ;
MANDLER, RN ;
ROSENBERG, GA ;
JEFFREY, C ;
BARGER, GR ;
GANDHI, B ;
MOORE, PM ;
ROGERS, LR ;
LISAK, D ;
SMITH, L ;
ELLISON, GW ;
BAUMHEFNER, RW ;
CRAIG, SL ;
JALBUT, SS ;
KATZ, E ;
CONWAY, KL ;
BURNS, JB ;
SHIBA, C ;
GIANG, DW ;
PETRIE, MD ;
GUARNACCIA, JB ;
ANDERSON, S ;
MCKEON, A ;
MCCARTHY, M ;
THOMAS, AB ;
VRIESENDORP, FJ ;
AUSTIN, SG ;
LINDSEY, JW ;
DIMACHKIE, M ;
CERRETA, E ;
KACHUCK, N ;
MCCARTHY, KA .
NEUROLOGY, 1995, 45 (07) :1268-1276